Haemonetics Corporation (HAE): Valuation
TTM figures as of June 27, 2026
Haemonetics Corporation trades at 48.5 times trailing earnings and a 6.23% free-cash-flow yield. On P/E that is higher than 51% of its own month-end history back to 2010. The Healthcare median P/E is 22.9.
Earnings yield 2.06%. Shareholder yield 2.14%. ROIC 6.6%. Piotroski F-score 7 of 9. Net debt $964.8M.
197 month-end valuation observations are on file, starting April 2010.
Sector comparison uses 2682 Healthcare names.
Frequently asked questions
Is HAE cheap versus its own history?
Haemonetics Corporation trades at 48.5 times trailing earnings and a 6.23% free-cash-flow yield. On P/E that is higher than 51% of its own month-end history back to 2010. The Healthcare median P/E is 22.9.
What is HAE's free-cash-flow yield?
Haemonetics Corporation currently yields 6.23% of market cap as trailing free cash flow.
Where do these valuation figures come from?
Yields and quality metrics are computed from the same SEC TTM figures as the financials page, against the live market cap. Historical bands reconstruct month-end market cap from split-adjusted closes and the share count in the units it was filed, then divide by those dollar totals. Nothing here is a third-party estimate.